17th Jun 2021 10:54
17 June 2021
Microsaic Systems plc
("Microsaic" or the "Company")
Result of Annual General Meeting
Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today were duly passed on a poll, the results of which are set out below:
|
| Votes For* | % of votes cast | Votes against | % votes cast | Votes withheld |
Ordinary Resolutions | ||||||
1 | To approve the audited accounts of the Company for the year ended 31 December 2020, together with the Directors' Report and Auditors' Report thereon
| 3,523,708,945 | 100.000 | - | - | 2,407,506 |
2 | To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the remuneration of the auditors
| 3,523,235,738 | 99.932 | 2,407,006 | 0.068 | 473,707 |
3 | To re-appoint Gerard Brandon as a Director of the Company
| 3,526,086,451 | 99.999 | 30,000 | 0.001 | - |
4 | To re-appoint Nigel Burton as a Director of the Company
| 3,526,086,451 | 99.999 | 30,000 | 0.001 | - |
5 | To authorise the Directors to allot equity securities up to an aggregate nominal amount of £202,545
| 3,523,401,451 | 99.923 | 2,715,000 | 0.077 | - |
Special Resolutions | ||||||
6 | To disapply statutory pre-emption rights up to an aggregate nominal amount of £151,909
| 3,429,049,709 | 97.247 | 97,066,742 | 2.753 | - |
7 | To adopt the new Articles of Association of the Company
| 3,526,086,451 | 99.999 | 30,000 | 0.001 | - |
* "Votes For" include votes giving the Chairman discretion.
Enquiries: | |
Microsaic Systems plc Glenn Tracey, CEO - Bevan Metcalf, FD | +44 (0) 1483 751 577 |
N+1 Singer (Nominated Adviser & Joint Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / George Tzimas (Corporate Finance) | |
Tom Salvesen (Corporate Broking) | |
Turner Pope Investments (TPI) Limited (Broker) Andy Thacker / James Pope | +44 (0) 20 3657 0050 |
About Microsaic (www.microsaic.com)
Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.
Related Shares:
Microsaic